Shares of Roivant Sciences Ltd.
gained about 6% in trading on Wednesday after the company said its experimental atopic dermatitis treatment met the primary endpoint in a Phase 3 clinical trial. The cream is being tested as a therapy for adults and children as young as 2 years old. Roivant said it expects topline data from another study for the same indication in May. The drug, called Vtama, is already approved to treat plaque psoriasis in adults. Roivant’s stock is up 2.9% so far this year, while the S&P 500
has gained 2.4%.